Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer

$ADAP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $ADAP alert in real time by email

PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 04, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Dr. Joanna (Jo) Brewer as Chief Scientific Officer (CSO) effective immediately.

"Jo Brewer is an exceptional scientific leader, and I am delighted that she has accepted the newly created CSO role, leading our ongoing scientific research, and developing future autologous and allogeneic therapies," said Adrian Rawcliffe, Adaptimmune's Chief Executive Officer. "Jo has a strong track record of building successful teams, driving innovation in cell therapy, as she worked on all of our autologous clinical programs and developed our allogeneic iPSC T-cell therapy platform. She has played a crucial role in our collaborations with Astellas and Genentech."

Most recently, Dr. Brewer served as Senior Vice President, Allogeneic Research at Adaptimmune since December 2019. In this role, she built the Allogeneic Research organization from the ground up and took the concept of iPSC-derived allogeneic T-cell therapies from an idea into the potential for an allogeneic candidate in the clinic. Prior to her SVP role, Dr. Brewer held a series of senior managerial roles within Adaptimmune's research organization. Her experience in immunotherapy and cell therapy at Adaptimmune and its predecessor companies spans more than 20 years and includes roles across the breadth of discovery. Before focussing solely on the allogeneic platform for the last three years, Dr. Brewer was one of the founding scientists at Adaptimmune who built multiple research teams working on the development of SPEAR T-cell therapies including NY-ESO (transitioned to GSK in 2018), ADP-A2M4 and ADP-A2AFP, as well as early next-generation approaches including the ADP-A2M4CD8 construct. Prior to joining Adaptimmune in 2009, Dr. Brewer held positions at Avidex, Medigene, and Immunocore. She holds a master's degree in Natural Sciences, and a Ph.D. in cellular signalling, both from the University of Cambridge, U.K.

About Adaptimmune 

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.

Forward-Looking Statements 

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2021, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances. 

Adaptimmune Contacts: 

Media Relations: 

Sébastien Desprez — VP, Corporate Affairs and Communications 

T: +44 1235 430 583 

M: +44 7718 453 176 

Sebastien.Desprez@adaptimmune.com 

Investor Relations: 

Juli P. Miller, Ph.D. — VP, Investor Relations 

T: +1 215 825 9310 

M: +1 215 460 8920 

Juli.Miller@adaptimmune.com 



Primary Logo

Get the next $ADAP alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ADAP

DatePrice TargetRatingAnalyst
7/30/2024$4.00Buy
H.C. Wainwright
5/30/2024$3.15Sector Outperform
Scotiabank
3/24/2023$3.60Buy
Bryan Garnier
1/3/2023$5.00Neutral → Buy
Guggenheim
11/9/2022$9.00Neutral → Buy
Mizuho
9/22/2021$6.00 → $7.00Equal-Weight
Wells Fargo
9/13/2021$6.00 → $7.00Market Perform
SVB Leerink
9/7/2021$5.00 → $6.00Market Perform
SVB Leerink
More analyst ratings

$ADAP
Press Releases

Fastest customizable press release news feed in the world

See more
  • Adaptimmune Provides Q4 and Full Year 2024 Business Update

    TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achievedLete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programsAt the end of 2024, Adaptimmune had Total Liquidity1 of $152 millionEvaluating all strategic options to maximize shareholder valuePhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy,

    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

    Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2024, before the US markets open on Thursday, March 20, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/13966. Call in information is as follows: 1-8

    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

    Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in the Guggenheim Securities SMID Cap Biotech Conference this February.Guggenheim Securities SMID Cap Biotech Conference, New York, NYFireside chat with Adrian Rawcliffe, CEO: February 6 at 3:00 p.m. ESTWebcast link: https://wsw.com/webcast/guggen2/adap/1969770 This event can also be accessed by visiting 'Events', under the 'News Center' tab, in the 'Investors & Media' section of Adaptimmune's website at www.adaptimmune.com.

    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ADAP
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ADAP
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ADAP
SEC Filings

See more

$ADAP
Leadership Updates

Live Leadership Updates

See more
  • Adaptimmune Provides Q4 and Full Year 2024 Business Update

    TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achievedLete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programsAt the end of 2024, Adaptimmune had Total Liquidity1 of $152 millionEvaluating all strategic options to maximize shareholder valuePhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy,

    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

    Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2024, before the US markets open on Thursday, March 20, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/13966. Call in information is as follows: 1-8

    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024

    Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 31, 2024) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the third quarter ended September 30, 2024, after the US markets close on Wednesday, November 13, 2024. Following the announcement, the Company will host a live webcast at 4:30 p.m. EDT (9:30 p.m. GMT).The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/13698. Call in information is as follows: +1-844-76

    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ADAP
Financials

Live finance-specific insights

See more
  • Adaptimmune Reports Q3 2024 Financial and Business Updates

    Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed in Q3; expect first commercial revenues in Q4 and the number of treated patients to accelerate throughout 2025Lete-cel IGNYTE-ESO pivotal trial primary analysis reports 42% overall response rate in synovial sarcoma and myxoid/round cell liposarcoma (MRCLS); full data at CTOS conference on November 16Company restructuring to prioritize commercial sarcoma franchise and R&D programs with highest potential return on invested capital and transformational benefit to patientsPlanned 33% reduction in headcount in Q1, 2025 as part of approximately $300 million

    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Adaptimmune Reports Q2 2024 Financial and Business Updates

    Adaptimmune received U.S. FDA accelerated approval of Tecelra® (afami-cel), the first approved engineered cell therapy for a solid tumorPatients can begin treatment journey; biomarker testing available; Adaptimmune systems ready to receive ordersAt the end of Q2, Adaptimmune had Total Liquidity[1] of $214.8 millionPhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 12, 2024) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reports financial results and business updates for the second quarter ended June 30, 2024. The Company will host a live webcast at 8:00 a.m. EDT (1:00 p.m. BST) tod

    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

    Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade Adaptimmune to hold webcast at https://www.gowebcasting.com/13428 on August 2, at 8:00 a.m. EDT Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced U.S. Food and Drug Administration (FDA) accelerated approval of TECELRA® (afamitresgene autoleucel) for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*0

    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ADAP
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more